title: Immunogenicity and other problems associated with the use of biopharmaceuticals.
abstract: Biopharmaceuticals are used widely for the treatment of cancer, chronic viral hepatitis, inflammatory, and autoimmune diseases. Biopharmaceuticals such as interferons are well tolerated for the most part with the most common adverse events observed being 'flu-like' symptoms that resolve rapidly after initial treatment. Prolonged treatment is associated, however, with more serious adverse events including leucopenia, thrombocytopenia, and neuropsychiatric effects, which may necessitate dose reduction or even cessation of treatment in some patients. Recombinant growth factors, such as erythropoietin (EPO), granulocyte colony-stimulating factor, or granulocyte macrophage colony-stimulating factor, are for the most part well tolerated, although severe complications have been reported in patients with cancer or chronic kidney disease treated with EPO. Similarly, treatment of patients with cancer with high doses of interleukin-2 is associated with significant toxicity. Treatment of chronic inflammatory diseases, such as rheumatoid arthritis, psoriasis, and Crohn's disease, with antitumor necrosis factor-alpha monoclonal antibodies is associated with an increased risk of granulomatous infections and, in particular, tuberculosis. The monoclonal antibody, natalizumab, that targets alpha4 integrins is effective in the treatment of multiple sclerosis but is associated with the activation of JC virus and development of progressive multifocal leukoencephalopathy. Repeated administration of recombinant proteins can cause a break in immune tolerance in some patients resulting in the production of a polyclonal antibody response that can adversely affect pharmacokinetics and clinical response. In addition, neutralizing antibodies that cross react with nonredundant essential proteins such as EPO can cause severe autoimmune reactions.
authors.affiliation: Laboratory of Viral Oncology, FRE3238 CNRS, Institut André Lwoff, 7 rue Guy Moquet, 94801 Villejuif, France.
authors.forename: Michael G
authors.initials: MG
authors.lastname: Tovey
authors.affiliation: Laboratory of Viral Oncology, FRE3238 CNRS, Institut André Lwoff, 94801 Villejuif, France.
authors.forename: Christophe
authors.initials: C
authors.lastname: Lallemand
keywords: adverse events; biopharmaceutical; cytokine; growth factor; immunogenicity; monoclonal antibody
references.citation: J Rheumatol. 2009 Aug;36(8):1631-8
references.pmid: 19567624
references.citation: Nat Biotechnol. 2010 Feb;28(2):105-6
references.pmid: 20139927
references.citation: J Neurol. 2009 Oct;256(10):1771-2
references.pmid: 19609591
references.citation: Verh K Acad Geneeskd Belg. 2009;71(1-2):51-71
references.pmid: 19739398
references.citation: Genes Immun. 2009 Jan;10(1):68-76
references.pmid: 19092842
references.citation: Neurology. 2007 Oct 2;69(14):1391-403
references.pmid: 17761550
references.citation: J Rheumatol. 2005 Nov;32(11):2130-5
references.pmid: 16265690
references.citation: N Engl J Med. 2005 Jan 27;352(4):351-61
references.pmid: 15673801
references.citation: J Clin Endocrinol Metab. 1980 Oct;51(4):691-7
references.pmid: 7419661
references.citation: Gastroenterology. 1995 Jun;108(6):1942-4
references.pmid: 7539390
references.citation: Neurology. 2003 Nov 11;61(9 Suppl 5):S13-7
references.pmid: 14610104
references.citation: Minerva Gastroenterol Dietol. 2010 Jun;56(2):233-43
references.pmid: 20485259
references.citation: Trends Immunol. 2007 Nov;28(11):482-90
references.pmid: 17964218
references.citation: Neurology. 2005 Jul 12;65(1):40-7
references.pmid: 16009883
references.citation: Arthritis Rheum. 1998 Apr;41(4):754
references.pmid: 9550494
references.citation: Proc Natl Acad Sci U S A. 2003 Mar 4;100(5):2610-5
references.pmid: 12604793
references.citation: Ann Rheum Dis. 2011 Jan;70(1):39-46
references.pmid: 20937671
references.citation: Proc Natl Acad Sci U S A. 2005 Mar 1;102(9):3372-7
references.pmid: 15728381
references.citation: Hum Mol Genet. 2009 Jun 1;18(11):2071-7
references.pmid: 19286670
references.citation: Blood. 2001 Dec 1;98(12):3241-8
references.pmid: 11719360
references.citation: Eur J Pharmacol. 2005 Oct 31;523(1-3):1-15
references.pmid: 16226745
references.citation: Med Oncol. 2000 Feb;17(1):64-9
references.pmid: 10713663
references.citation: Expert Opin Drug Saf. 2009 Jul;8(4):459-72
references.pmid: 19548860
references.citation: Clin Rheumatol. 2009 Oct;28(10):1241-3
references.pmid: 19653058
references.citation: Diabetes Care. 1993 Dec;16 Suppl 3:155-65
references.pmid: 8299472
references.citation: Neurology. 1995 Jun;45(6 Suppl 6):S44-9
references.pmid: 7783912
references.citation: Antivir Ther. 2007;12(8):1225-35
references.pmid: 18240862
references.citation: Blood. 2009 May 14;113(20):4834-40
references.pmid: 19264918
references.citation: Clin Pharmacokinet. 2001;40(7):539-51
references.pmid: 11510630
references.citation: Arthritis Rheum. 1998 Sep;41(9):1552-63
references.pmid: 9751087
references.citation: Clin Rheumatol. 2008 Nov;27(11):1467-8
references.pmid: 18704546
references.citation: N Engl J Med. 2008 Oct 23;359(17):1786-801
references.pmid: 18946064
references.citation: N Engl J Med. 2005 Jun 30;352(26):2705-13
references.pmid: 15987919
references.citation: Cytokine. 2005 Jan 21;29(2):56-66
references.pmid: 15598439
references.citation: Mult Scler. 2011 Feb;17(2):255-6
references.pmid: 21177318
references.citation: Curr Med Chem. 2010;17(29):3297-302
references.pmid: 20712575
references.citation: Aliment Pharmacol Ther. 2007 May 15;25(10):1153-62
references.pmid: 17451561
references.citation: Dev Biol (Basel). 2003;112:15-21
references.pmid: 12762500
references.citation: J Rheumatol. 2007 Feb;34(2):380-5
references.pmid: 17013997
references.citation: Semin Oncol. 2000 Dec;27(6 Suppl 12):53-61
references.pmid: 11226001
references.citation: Methods. 2006 Apr;38(4):237-52
references.pmid: 16481200
references.citation: Curr Biol. 2010 Apr 13;20(7):R328-33
references.pmid: 20392426
references.citation: Semin Arthritis Rheum. 2008 Jun;37(6):381-7
references.pmid: 17977585
references.citation: Mod Rheumatol. 2009;19(4):401-6
references.pmid: 19440814
references.citation: J Interferon Cytokine Res. 2000 Nov;20(11):971-82
references.pmid: 11096454
references.citation: N Engl J Med. 2008 Mar 13;358(11):1109-17
references.pmid: 18337601
references.citation: J Int Med Res. 2007 Mar-Apr;35(2):173-87
references.pmid: 17542405
references.citation: JAMA. 2006 May 17;295(19):2275-85
references.pmid: 16705109
references.citation: Lancet Neurol. 2010 Apr;9(4):381-90
references.pmid: 20163990
references.citation: N Engl J Med. 2002 Feb 14;346(7):469-75
references.pmid: 11844847
references.citation: Ann Rheum Dis. 2010 Jun;69(6):976-86
references.pmid: 20447957
references.citation: J Dermatolog Treat. 2009;20(2):100-8
references.pmid: 18923992
references.citation: Leukemia. 2008 Nov;22(11):1990-8
references.pmid: 18843285
references.citation: Expert Opin Biol Ther. 2010 Mar;10(3):421-9
references.pmid: 20095876
references.citation: Am J Gastroenterol. 2002 Mar;97(3):767-8
references.pmid: 11922585
references.citation: Lancet. 1990 Feb 24;335(8687):434-7
references.pmid: 1968169
references.citation: Clin Cancer Res. 1999 Jun;5(6):1353-61
references.pmid: 10389919
references.citation: Muscle Nerve. 2010 May;41(5):723-7
references.pmid: 20405504
references.citation: Arthritis Rheum. 1999 Mar;42(3):569-73
references.pmid: 10088781
references.citation: Arch Dermatol. 2011 Jan;147(1):72-6
references.pmid: 20855675
references.citation: Ann Neurol. 2010 Sep;68(3):384-91
references.pmid: 20818792
references.citation: Nat Genet. 2006 May;38(5):550-5
references.pmid: 16642019
references.citation: Int MS J. 2009 Sep;16(3):75-6
references.pmid: 19899240
references.citation: Arthritis Rheum. 2009 Jun;60(6):1845-50
references.pmid: 19479858
references.citation: Clin Immunol. 2006 Jan;118(1):42-50
references.pmid: 16260183
references.citation: Onco Targets Ther. 2010 Jun 24;3:53-67
references.pmid: 20616957
references.citation: Neurology. 2004 Jun 8;62(11):2031-7
references.pmid: 15184610
references.citation: Ann Rheum Dis. 2010 Mar;69(3):522-8
references.pmid: 19854715
references.citation: N Engl J Med. 1991 Aug 15;325(7):467-72
references.pmid: 1852181
references.citation: N Engl J Med. 2009 Aug 6;361(6):580-93
references.pmid: 19625712
references.citation: J Gastroenterol. 1996 Oct;31(5):723-7
references.pmid: 8887042
references.citation: Am J Manag Care. 2010 Jun;16(6 Suppl):S164-70
references.pmid: 20615052
references.citation: J Clin Invest. 1984 Sep;74(3):906-13
references.pmid: 6590569
references.citation: Semin Hematol. 2010 Apr;47(2):115-23
references.pmid: 20350658
references.citation: Pharm Res. 2010 Sep;27(9):1812-24
references.pmid: 20499141
references.citation: Acta Neurol Scand. 2005 Sep;112(3):194-6
references.pmid: 16097964
references.citation: Ann Rheum Dis. 2009 Dec;68(12):1921-4
references.pmid: 19054818
references.citation: Ann Rheum Dis. 2010 Sep;69(9):1691-3
references.pmid: 19628820
references.citation: Clin Exp Med. 2004 Apr;3(4):199-210
references.pmid: 15103510
references.citation: Lancet Neurol. 2010 Apr;9(4):438-46
references.pmid: 20298967
references.citation: Semin Arthritis Rheum. 2011 Feb;40(4):330-7
references.pmid: 20864146
references.citation: Neurol Sci. 2011 Feb;32(1):181-2
references.pmid: 21052756
references.citation: J Viral Hepat. 2009 Jun;16(6):388-96
references.pmid: 19200137
references.citation: Ann Oncol. 2007 Feb;18(2):226-32
references.pmid: 17116643
references.citation: J Interferon Cytokine Res. 2008 Jun;28(6):393-404
references.pmid: 18593334
references.citation: Arthritis Rheum. 2009 Aug;60(8):2472-9
references.pmid: 19644887
references.citation: EMBO Mol Med. 2011 Mar;3(3):142-52
references.pmid: 21268286
references.citation: Arthritis Rheum. 2007 Dec;56(12):3989-94
references.pmid: 18050197
references.citation: Rheumatology (Oxford). 2007 Jun;46(6):927-30
references.pmid: 17384181
references.citation: Drug Saf. 2010 Nov 1;33(11):969-83
references.pmid: 20925435
references.citation: Aliment Pharmacol Ther. 2003 Sep 15;18(6):549-58
references.pmid: 12969081
references.citation: J Interferon Cytokine Res. 2010 Oct;30(10):715-26
references.pmid: 20874249
references.citation: Neurology. 2005 Jul 12;65(1):48-55
references.pmid: 16009884
references.citation: Curr Opin Neurol. 2010 Jun;23(3):226-33
references.pmid: 20442571
references.citation: Arch Dermatol. 2008 Oct;144(10):1341-9
references.pmid: 18936398
references.citation: J Clin Virol. 2010 Aug;48(4):291-3
references.pmid: 20558102
references.citation: Biologics. 2008 Jun;2(2):189-99
references.pmid: 19707353
references.citation: Arthritis Rheum. 2006 Feb;54(2):408-20
references.pmid: 16447217
references.citation: Semin Oncol. 1998 Feb;25(1 Suppl 1):39-47
references.pmid: 9482539
references.citation: Mult Scler. 2009 Dec;15(12):1532-3
references.pmid: 20019096
references.citation: Clin Rheumatol. 2010 Sep;29(9):1021-9
references.pmid: 20556450
references.citation: Arthritis Rheum. 2009 Jul;60(7):1991-7
references.pmid: 19565491
references.citation: Proc Natl Acad Sci U S A. 2006 Apr 11;103(15):5941-6
references.pmid: 16585503
references.citation: Cancer. 2007 Jul 1;110(1):103-11
references.pmid: 17516438
references.citation: Arthritis Res Ther. 2009;11(3):R69
references.pmid: 19442287
references.citation: Drugs. 2010 Jul 30;70(11):1445-76
references.pmid: 20614951
references.citation: Expert Opin Biol Ther. 2010 Jun;10(6):959-69
references.pmid: 20415630
references.citation: Curr Opin Oncol. 2010 Jul;22(4):307-11
references.pmid: 20498598
references.citation: J Immunol Methods. 2010 Apr 30;356(1-2):18-28
references.pmid: 20298696
references.citation: Semin Thromb Hemost. 2000;26(2):167-71
references.pmid: 10919409
references.citation: J Interferon Cytokine Res. 2009 Feb;29(2):93-104
references.pmid: 19000020
references.citation: Semin Arthritis Rheum. 2010 Apr;39(5):327-46
references.pmid: 19117595
references.citation: Arthritis Rheum. 2009 Sep;60(9):2558-64
references.pmid: 19714582
references.citation: Pharm World Sci. 2005 Dec;27(6):423-31
references.pmid: 16341948